Vanderbilt-discovered cancer killing compound is now available through Boehringer Ingelheim open science portal opnMe
May 30, 2024
May 30, 2024
NASHVILLE, Tennessee, May 30 -- Vanderbilt University issued the following news:
Researchers in the lab of Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research, have added BI-0474 as the second molecule co-discovered by Vanderbilt to the open science portal opnMe.com, an initiative being driven by biopharmaceutical company Boehringer Ingelheim.
The KRASG12C inhibitor is freely available on opnMe.
BI-0474 is an irreversible covalent inhibitor of G12C m . . .
Researchers in the lab of Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research, have added BI-0474 as the second molecule co-discovered by Vanderbilt to the open science portal opnMe.com, an initiative being driven by biopharmaceutical company Boehringer Ingelheim.
The KRASG12C inhibitor is freely available on opnMe.
BI-0474 is an irreversible covalent inhibitor of G12C m . . .